Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
The manufacturing conditions of Zaltrap / Eylea biosimilar from the CHO stable cell line need to be optimized by clients.
Syd Labs does not sell Zaltrap / Eylea biosimilar as a drug in any country or area.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Aflibercept (trade name Zaltrap, Eylea) is a fusion protein inhibiting vascular endothelial growth factor (VEGF), is used for the treatment of wet macular degeneration and metastatic colorectal cancer.
C013: Zaltrap / Eylea Biosimilar Stable Cell Line (CHO)
The yield of Zaltrap / Eylea biosimilar from the CHO stable cell line was above 2.1 g/L in a 3 liter manufacturing.
The Zaltrap / Eylea biosimilar stable cell line alone can be transfered alone or together with the technology of process development and/or antibody purification.
Copyright © 2009-2022 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.